K Tsung
Overview
Explore the profile of K Tsung including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
573
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Le H, Lee N, Tsung K, Norton J
J Immunol
. 2001 Dec;
167(12):6765-72.
PMID: 11739491
The antitumor immune response activated by IL-12, especially by a combination of cyclophosphamide and IL-12 (Cy+IL-12), is clinically significant in certain experimental tumor models, in that a number of well-established...
2.
Carroll M, Overwijk W, Surman D, Tsung K, Moss B, Restifo N
J Natl Cancer Inst
. 1998 Dec;
90(24):1881-7.
PMID: 9862625
Background: Construction of recombinant viruses that can serve as vaccines for the treatment of experimental murine tumors has recently been achieved. The cooperative effects of immune system modulators, including cytokines...
3.
Overwijk W, Tsung A, Irvine K, Parkhurst M, Goletz T, Tsung K, et al.
J Exp Med
. 1998 Jul;
188(2):277-86.
PMID: 9670040
Many tumor-associated antigens are nonmutated, poorly immunogenic tissue differentiation antigens. Their weak immunogenicity may be due to "self"-tolerance. To induce autoreactive T cells, we studied immune responses to gp100/pmel 17,...
4.
Peplinski G, Tsung K, Norton J
Surg Oncol Clin N Am
. 1998 Jun;
7(3):575-88.
PMID: 9624218
Recombinant vaccinia virus may be an ideal viral vector for cancer gene therapy. It has a large genome that is able to be engineered for the insertion and simultaneous expression...
5.
Tsung K, Meko J, Tsung Y, Peplinski G, Norton J
J Immunol
. 1998 May;
160(3):1369-77.
PMID: 9570556
Previous studies have demonstrated eradication of small (4-8 mm) established murine MCA207 sarcomas by treatment with systemic IL-12. Analysis of the mechanism has revealed a cellular and molecular immune response...
6.
Oertli D, Marti W, Norton J, Tsung K
Clin Exp Immunol
. 1997 Nov;
110(1):144-9.
PMID: 9353162
The current study was designed to test the ability of recombinant Vaccinia virus (rVV) encoding essential components of an artificial antigen-presenting cell to activate antigen-specific T cells in vitro. We...
7.
Overwijk W, Surman D, Tsung K, Restifo N
Methods
. 1997 Jun;
12(2):117-23.
PMID: 9184376
The use of recombinant and synthetic vaccines in the treatment of cancer has recently been explored using model tumor associated antigens (TAA), many of which do not model the immunological...
8.
Tsung K, Meko J, Peplinski G, Tsung Y, Norton J
J Immunol
. 1997 Apr;
158(7):3359-65.
PMID: 9120294
Although IL-12 possesses the most potent single-cytokine antitumor efficacy, the mechanism by which IL-12 exerts its antitumor activities remains unclear. Using a complete tumor regression model induced by IL-12 treatment,...
9.
Marti W, Oertli D, Meko J, Norton J, Tsung K
J Immunol Methods
. 1997 Jan;
200(1-2):191-8.
PMID: 9005958
The possibility of inducing antigen-presenting capacity in cells normally lacking such capacity, currently represents a major goal in vaccine research. To address this issue we attempted to generate 'artificial' APC...
10.
Oertli D, Marti W, Norton J, Tsung K
J Gen Virol
. 1996 Dec;
77 ( Pt 12):3121-5.
PMID: 9000106
Using a series of new insertion/expression vectors, we constructed a set of recombinant vaccinia viruses (recVV) encoding the murine T cell costimulatory molecules mB7-1 or mB7-2, or both together in...